Rezaeizadeh Golnaz, Hantoushzadeh Sedigheh, Ghiasi Sima, Nikfar Shekoufeh, Abdollahi Mohammad
Faculty of Pharmacy and Pharmaceutical Sciences Research Center, TUMS, Tehran 1417614411, Iran.
Curr Pharm Biotechnol. 2016;17(11):934-48.
Preterm birth is a worldwide tragedy with a high incidence. Several medications are used to inhibit acute preterm labor, but tocolysis by these medicines do not extend pregnancy beyond 1-2 days.
The purpose of this study was to discover new medications from plant extracts or their active compounds which inhibit the uterine contractions in order to treat preterm labor.
PubMed, Google Scholar, Scopus and IranMedex databases were searched up to 1st February 2012 with the most relevant keywords.
All studies in which plant extracts or their active compounds inhibited the uterine contractions both in vivo and in vitro were included.
Of initial search, 259 records were reviewed and finally 72 were included among which only 31 studies isolated an active compound from the plants extract belonging mostly to classes of flavonoids and terpenes classes. Flavonoids have been known as a phosphodiesterase (PDE) and a protein kinase C (PKC) inhibitor. It seems that the uterolytic activity of reviewed flavonoids such as naringenin, kaempferol and quercetin, especially in a calcium free solution, was via these inhibitory pathways.
Laboring uterus response to dissimilar tocolytics differs from that of non-laboring uterus. In order to find a treatment for preterm labor, future studies should focus on the laboring uterus and also determine the structure activity relationship of the different tocolytics. This systematic review was registered to the PROSPERO with code number CRD42015027551.
早产是一个全球范围内发病率很高的悲剧。有几种药物被用于抑制急性早产,但这些药物的宫缩抑制作用并不能使孕期延长超过1 - 2天。
本研究的目的是从植物提取物或其活性化合物中发现新的药物,以抑制子宫收缩从而治疗早产。
截至2012年2月1日,使用最相关的关键词在PubMed、谷歌学术、Scopus和伊朗医学数据库中进行了检索。
纳入所有植物提取物或其活性化合物在体内和体外均能抑制子宫收缩的研究。
在初步检索中,共审查了259条记录,最终纳入72条,其中只有31项研究从植物提取物中分离出活性化合物,这些化合物大多属于黄酮类和萜类。黄酮类化合物已知是磷酸二酯酶(PDE)和蛋白激酶C(PKC)抑制剂。似乎所审查的黄酮类化合物如柚皮苷、山奈酚和槲皮素的子宫溶解活性,尤其是在无钙溶液中,是通过这些抑制途径实现的。
分娩期子宫对不同宫缩抑制剂的反应与未分娩子宫不同。为了找到早产的治疗方法,未来的研究应关注分娩期子宫,并确定不同宫缩抑制剂的构效关系。本系统评价已在PROSPERO注册,注册号为CRD42015027551。